Skip to main content
Erschienen in: Virchows Archiv 5/2007

01.11.2007 | Review and Perspective

Lymphatic vessels are present in phosphaturic mesenchymal tumours

verfasst von: K. Williams, A. Flanagan, A. Folpe, R. Thakker, N. A. Athanasou

Erschienen in: Virchows Archiv | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Oncogenic osteomalacia (OO) is an acquired form of hypophosphataemic osteomalacia, which is associated most commonly with the development of a benign phosphaturic mesenchymal tumour mixed connective tissue type (PMTMCT). PMTMCTs are generally well‑vascularised tumours, and many have in the past been classified as haemangiomas and haemangiopericytomas. Although these tumours show some morphological variation, it has been proposed that they represent a distinct histopathological entity. Our aim in this study was to determine by immunohistochemistry the vascular profile of PMTMCT. Using monoclonal antibodies directed against several vascular markers, including the lymphatic endothelial cell antigens LYVE‑1 and podoplanin, we found that PMTMCTs, in contrast to haemangiomas and haemangiopericytomas, contain lymphatic vessels. Taken with previous observations that PMTMCTs over‑express FGF23 and other gene products, this finding provides further evidence that most osteomalacia‑associated mesenchymal tumours represent a discrete pathological entity.
Literatur
1.
Zurück zum Zitat Aschinberg LC, Solomon LM, Zeis PM, Justice P, Rosenthal IM (1977) Vitamin D‑resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 91:56–60PubMedCrossRef Aschinberg LC, Solomon LM, Zeis PM, Justice P, Rosenthal IM (1977) Vitamin D‑resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 91:56–60PubMedCrossRef
2.
Zurück zum Zitat Auguste P, Javerzat S, Bikfalvi A (2003) Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 314:157–166PubMedCrossRef Auguste P, Javerzat S, Bikfalvi A (2003) Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 314:157–166PubMedCrossRef
3.
Zurück zum Zitat Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG (1999) LYVE‑1, a new homologue of the CD44 glycoprotein, is a lymph‑specific receptor for hyaluronan. J Cell Biol 144:789–801PubMedCrossRef Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG (1999) LYVE‑1, a new homologue of the CD44 glycoprotein, is a lymph‑specific receptor for hyaluronan. J Cell Biol 144:789–801PubMedCrossRef
4.
Zurück zum Zitat Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMed Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMed
6.
Zurück zum Zitat De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102–1110PubMedCrossRef De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102–1110PubMedCrossRef
7.
Zurück zum Zitat Drezner MK (1999) Tumour‑induced osteomalacia. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams and Wilkins, Washington, pp 331–337 Drezner MK (1999) Tumour‑induced osteomalacia. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams and Wilkins, Washington, pp 331–337
8.
Zurück zum Zitat Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O’Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30PubMedCrossRef Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O’Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30PubMedCrossRef
9.
Zurück zum Zitat Fukumoto S, Yamashita T (2002) Fibroblast growth factor‑23 is the phosphaturic factor in tumor‑induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11:385–389PubMedCrossRef Fukumoto S, Yamashita T (2002) Fibroblast growth factor‑23 is the phosphaturic factor in tumor‑induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11:385–389PubMedCrossRef
10.
Zurück zum Zitat Haviv YS, Silver J (2000) Late onset oncogenic osteomalacia‑associated with neurofibromatosis type II. Clin Nephrol 54:429–430PubMed Haviv YS, Silver J (2000) Late onset oncogenic osteomalacia‑associated with neurofibromatosis type II. Clin Nephrol 54:429–430PubMed
11.
Zurück zum Zitat Hultberg BM, Svanholm H (1989) Immunohistochemical differentiation between lymphangiographically verified lymphatic vessels and blood vessels. Virchows Arch A Pathol Anat Histopathol 414:209–215PubMedCrossRef Hultberg BM, Svanholm H (1989) Immunohistochemical differentiation between lymphangiographically verified lymphatic vessels and blood vessels. Virchows Arch A Pathol Anat Histopathol 414:209–215PubMedCrossRef
12.
Zurück zum Zitat Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K (2002) Blockade of vascular endothelial growth factor receptor‑3 signaling inhibits fibroblast growth factor‑2‑induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 99:8868–8873PubMedCrossRef Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K (2002) Blockade of vascular endothelial growth factor receptor‑3 signaling inhibits fibroblast growth factor‑2‑induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 99:8868–8873PubMedCrossRef
13.
Zurück zum Zitat Lever EG, Pettingale KW (1983) Albright’s syndrome associated with a soft‑tissue myxoma and hypophosphataemic osteomalacia. Report of a case and review of the literature. J Bone Joint Surg Br 65:621–626PubMed Lever EG, Pettingale KW (1983) Albright’s syndrome associated with a soft‑tissue myxoma and hypophosphataemic osteomalacia. Report of a case and review of the literature. J Bone Joint Surg Br 65:621–626PubMed
14.
Zurück zum Zitat McMurtry CT, Godschalk M, Malluche HH, Geng Z, Adler RA (1993) Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature. J Am Geriatr Soc 41:983–985PubMed McMurtry CT, Godschalk M, Malluche HH, Geng Z, Adler RA (1993) Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature. J Am Geriatr Soc 41:983–985PubMed
15.
Zurück zum Zitat Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P (2003) FGF‑23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692PubMedCrossRef Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P (2003) FGF‑23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692PubMedCrossRef
16.
Zurück zum Zitat Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K (1998) Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 46:165–176PubMed Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K (1998) Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 46:165–176PubMed
17.
Zurück zum Zitat Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor‑induced osteomalacia. Proc Natl Acad Sci U S A 98:6500–6505PubMedCrossRef Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor‑induced osteomalacia. Proc Natl Acad Sci U S A 98:6500–6505PubMedCrossRef
18.
Zurück zum Zitat Shin JW, Min M, Larrieu-Lahargue F, Canron X, Kunstfeld R, Nguyen L, Henderson JE, Bikfalvi A, Detmar M, Hong YK (2006) Prox1 promotes lineage‑specific expression of fibroblast growth factor (FGF) receptor‑3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell 17:576–584PubMedCrossRef Shin JW, Min M, Larrieu-Lahargue F, Canron X, Kunstfeld R, Nguyen L, Henderson JE, Bikfalvi A, Detmar M, Hong YK (2006) Prox1 promotes lineage‑specific expression of fibroblast growth factor (FGF) receptor‑3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell 17:576–584PubMedCrossRef
19.
Zurück zum Zitat Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T (2004) Venous sampling for fibroblast growth factor‑23 confirms preoperative diagnosis of tumor‑induced osteomalacia. J Clin Endocrinol Metab 89:3979–3982PubMedCrossRef Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T (2004) Venous sampling for fibroblast growth factor‑23 confirms preoperative diagnosis of tumor‑induced osteomalacia. J Clin Endocrinol Metab 89:3979–3982PubMedCrossRef
20.
Zurück zum Zitat Turner RR, Beckstead JH, Warnke RA, Wood GS (1987) Endothelial cell phenotypic diversity. In situ demonstration of immunologic and enzymatic heterogeneity that correlates with specific morphologic subtypes. Am J Clin Pathol 87:569–575PubMed Turner RR, Beckstead JH, Warnke RA, Wood GS (1987) Endothelial cell phenotypic diversity. In situ demonstration of immunologic and enzymatic heterogeneity that correlates with specific morphologic subtypes. Am J Clin Pathol 87:569–575PubMed
21.
Zurück zum Zitat Weidner N, Bar RS, Weiss D, Strottmann MP (1985) Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55:1691–1705PubMedCrossRef Weidner N, Bar RS, Weiss D, Strottmann MP (1985) Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55:1691–1705PubMedCrossRef
22.
Zurück zum Zitat Weidner N, Santa Cruz D (1987) Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59:1442–1454PubMedCrossRef Weidner N, Santa Cruz D (1987) Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59:1442–1454PubMedCrossRef
23.
Zurück zum Zitat Xu H, Edwards JR, Espinosa O, Banerji S, Jackson DG, Athanasou NA (2004) Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. Hum Pathol 35:857–861PubMedCrossRef Xu H, Edwards JR, Espinosa O, Banerji S, Jackson DG, Athanasou NA (2004) Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. Hum Pathol 35:857–861PubMedCrossRef
Metadaten
Titel
Lymphatic vessels are present in phosphaturic mesenchymal tumours
verfasst von
K. Williams
A. Flanagan
A. Folpe
R. Thakker
N. A. Athanasou
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 5/2007
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-007-0471-y

Weitere Artikel der Ausgabe 5/2007

Virchows Archiv 5/2007 Zur Ausgabe

Neu im Fachgebiet Pathologie